Business & Industry
- Pfizer enters into exclusive licensing agreement with 3SBio
- Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years
- Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD
- BlueRock Therapeutics announces publication in Nature of 18-month data from Phase 1 clinical trial for bemdaneprocel, an investigational cell therapy for Parkinson's disease
- European Commission approves Pfizer's RSV vaccine ABRYSVO® to help protect adults aged 18-59 against RSV lower respiratory tract disease
Research & Development
- Candidate drug that boosts protective brain protein in mice has potential to treat Alzheimer's disease
- Purdue center offers first comprehensive open access database of all clinically tested drugs
- Diabetes drug gives hope for new treatment for prostate cancer
- Generative AI on track to shape the future of drug design
- Head-to-head trial compares weight loss drugs
- New research offers hope for diabetic neuropathy sufferers
- Drug to slow Alzheimer's well tolerated outside of clinical trial setting
Conferences & Events
- New insights into T and B cells offer hope for autoimmune disease sufferers
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
Regulatory Affairs
- FDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
- FDA approves new treatment for hemophilia A or B
- FDA approves nasal spray influenza vaccine for self- or caregiver-administration
- FDA approves first nasal spray for treatment of anaphylaxis
- FDA approves nonsteroidal treatment for Duchenne muscular dystrophy